Area of research
Oncology · Pharmacology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Microbial Natural Products and Biosynthesis, Cholangiocarcinoma and Gallbladder Cancer Studies, and RNA modifications and cancer.
Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation
<scp>tRF</scp>‐34‐<scp>P4R8YP9LON4VHM</scp> Promotes Hepatocellular Carcinoma Progression and Tumour Cell‐Induced Angiogenesis via the <scp>MEK</scp>/<scp>ERK</scp> Pathway
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer
Anlotinib potentiates anti‐PD1 immunotherapy via transferrin receptor‐dependent CD8<sup>+</sup> T‐cell infiltration in hepatocellular carcinoma
Enhancement of gemcitabine sensitivity in intrahepatic cholangiocarcinoma through Saikosaponin-a mediated modulation of the p-AKT/BCL-6/ABCA1 axis
Exploring the functional role of tRF-39-8HM2OSRNLNKSEKH9 in hepatocellular carcinoma
PANoptosis-based molecular subtyping and HPAN-index predicts therapeutic response and survival in hepatocellular carcinoma
Uncovering the mechanism of Kang-ai injection for treating intrahepatic cholangiocarcinoma based on network pharmacology, molecular docking, and in vitro validation
CLEC1B is a Promising Prognostic Biomarker and Correlated with Immune Infiltration in Hepatocellular Carcinoma
Sphingomyelin Phodiesterase Acid-Like 3A Promotes Hepatocellular Carcinoma Growth Through the Enhancer of Rudimentary Homolog
Mucin 1 promotes tumor progression through activating WNT/β-catenin signaling pathway in intrahepatic cholangiocarcinoma
Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma
Guaiane sesquiterpenes and isopimarane diterpenes from an endophytic fungus Xylaria sp.